A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients th...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: You, Byung Chul, Kim, Young Seok, Kim, Hun il, Kim, Se Hun, Park, Seung Sik, Seo, Yu Ri, Kim, Sang Gyune, Lee, Se Whan, Kim, Hong Soo, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Association for the Study of the Liver 2012
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://ncbi.nlm.nih.gov/pubmed/23091807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2012.18.3.272
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky